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Abstract  65 
 66 
Gene transcription occurs in short bursts interspersed with silent periods, and these kinetics can be 67 
altered by promoter structure. The effect of alternate promoter architecture on transcription bursting is 68 
not known. We studied the human prolactin (hPRL) gene that contains two promoters, a pituitary-69 
specific promoter that requires the transcription factor Pit-1, and displays dramatic transcriptional 70 
bursting activity, and an alternate upstream promoter that is active in non-pituitary tissues. We studied 71 
large hPRL genomic fragments with luciferase reporters, and used bacterial artificial chromosome 72 
(BAC) recombineering to manipulate critical promoter regions. Stochastic switch mathematical 73 
modelling of single-cell time-lapse luminescence image data revealed that the Pit-1-dependent 74 
promoter showed longer, higher-amplitude transcriptional bursts. Knockdown studies confirmed that 75 
the presence of Pit-1 stabilised and prolonged periods of active transcription. Pit-1 therefore plays an 76 




Prolactin is a multifunctional mammalian hormone with a major role in lactation as well as other 81 
biological functions, including reproduction, immunomodulation and behaviour [1, 2]. This 82 
polypeptide hormone mainly originates in the lactotroph cells of the anterior pituitary gland, but is 83 
also expressed at extra-pituitary sites, such as brain, decidualised endometrium, myometrium and 84 
circulating lymphocytes, and hence requires tissue-specific transcriptional control mechanisms to 85 
regulate its functional versatility [1-3].  86 
 87 
The human PRL (hPRL) gene is located on the short arm of chromosome 6 and consists of five 88 
coding exons within a region of 10 kb. The gene has two distinct, alternative promoter elements that 89 
are 5.8 kb apart and show selective and tissue-specific activation [2, 4]. The proximal promoter is 90 
located immediately upstream of exon 1b and regulates hPRL transcription in the pituitary gland. This 91 
is often referred to as the pituitary-specific promoter and contains multiple binding sites for the 92 
pituitary-specific transcription factor Pit-1 [5, 6]. In lymphocytes and human endometrial cells, hPRL 93 
expression has been shown to be driven by an alternative promoter, upstream of the pituitary 94 
transcriptional start site [7]. This evolved from a long terminal repeat-like transposon, resulting in 95 
transcription of the additional exon 1a, giving rise to mRNA that is 150 bp longer than the pituitary 96 
mRNA [2, 8]. The different sized transcripts do not give rise to different protein isoforms, but are 97 
believed to contribute an additional level of regulation of PRL transcription in different cellular and 98 
functional contexts (pituitary versus extra-pituitary) by influencing the stability or translational 99 
efficiency of alternatively transcribed messages [2, 8]. Expression of the longer alternative promoter 100 
transcript has classically been viewed as a product of extra-pituitary sites, and considered to be Pit-1 101 
independent [4, 9, 10].  102 
 103 
Pit-1 (also known as POU1F1) is a member of the POU family of transcription factors that are 104 
characterised by the presence of a bipartite DNA binding domain, known as the POU domain [11]. It 105 
is essential for the differentiation of lactotroph, somatotroph and thyrotroph cells; Snell and Jackson 106 
dwarf mouse models carry mutations in the Pit-1 gene and show no development of these pituitary 107 
cell types [6], and Pit-1 mutations commonly result in hypopituitarism [12]. Additionally, Pit-1 108 
binding has been shown to play a crucial role in both basal and hormonally induced activity of the 109 
hPRL promoter [13-15].  110 
 111 
The hPRL genomic locus has many conserved regions far upstream of the transcriptional start site. 112 
Outside of the genomic locus, the PRL gene is surrounded by over 1Mb of non-coding DNA, a gene 113 
desert which could have a functional impact on hPRL regulation [16]. It has therefore been important 114 
to develop strategies for studying the transcription control function of the complete genomic region. 115 
BAC based reporter systems permit the inclusion of far-distant regulatory elements and can prove 116 
particularly beneficial in analysing function of promoters that comprise a complex array of cis-acting 117 
regulatory elements [7, 17, 18]. We previously generated a BAC reporter construct which spanned 118 
163Kb of the hPRL genomic locus including 115kb upstream and 38kb down-stream of the PRL gene 119 
and expressed firefly luciferase (Luc) under the control of the entire hPRL gene  (referred to as hPRL 120 
WT BAC) [18].  121 
 122 
In our earlier work, single cell imaging of the hPRL WT BAC in pituitry cell lines and tissues,  123 
showed that the hPRL gene displays dramttic pulses in transcriptional activity [19, 20].  This activity 124 
has been observed for many other genes, including the hGH (human growth hormone) gene  [21], and 125 
appears to be a general phenomenon that is intrinsic to gene regulation [21-27]. The characteristics of 126 
these transcriptional pulses may be susceptible to modulation, as part of normal physiological control, 127 
and this might be expected to impact on overall levels of gene expression. In the present study, to 128 
study the role of Pit-1, we have compared the hPRL WT BAC with a construct in which the entire 5kb 129 
pituitary promoter was deleted, leaving intact exon 1a and the upstream promoter (referred to as hPRL 130 
PitProKO BAC). We compared the transcriptional behaviour of the two constructs when they were 131 
stably transfected into GH3 pituitary cell lines and found that the alternate promoters directed distinct 132 
patterns of transcriptional bursting in single cells. We examined the role of Pit-1 binding sites and the 133 
effect of modulation of Pit-1 levels in pituitary cells, and found that rather than just being necessary 134 
for transcription, the binding of Pit-1 regulates the timing of hPRL transcription. These data suggest a 135 
new and unsuspected function of this well studied transcription factor in regulating the dynamics of 136 
pituitary-specific gene expression in an important tissue model for the control of endocrine function.  137 
Material and Methods 138 
 139 
Generation of hPRL pituitary promoter knock-out BAC (hPRL PitProKO BAC) 140 
The generation of hPRL WT BAC with Luc reporter has been described previously [18]. The hPRL 141 
WT BAC spans 163 kb of the human PRL genomic locus including 115 kb upstream and 38 kb 142 
downstream of the PRL gene (10kb) and expresses the luciferase reporter gene under the control of 143 
both the hPRL proximal and alternative promoters. In order to study specific prolactin gene activation 144 
via the alternative promoter, we sought to remove pituitary-specific promoter elements from the hPRL 145 
WT BAC by the targeting strategy based on the seamless recombineering technology [28]. Briefly, 146 
the ~5kb hPRL proximal promoter was first replaced with the GalK (E.coli galactokinase k gene) 147 
coding sequence. A positive recombinant selected on galactose containing minimal media, was 148 
subjected to a second round of recombination to remove the inserted GalK sequence and replace with 149 
the short (256bp) immediate hPRL promoter sequence necessary for transcription initiation which 150 
also contains the alternative RNA splice acceptor site at position -246 relative to Luc translation start 151 
site [18]. Within this region 3 Pit1 binding sites are found, these elements were mutated in vitro (see 152 
site directed mutagenesis below) prior to recombination to remove remnants of pituitary-specific 153 
regulatory elements. Positive recombinants were identified through glycerol/deoxygalactose screening 154 
and BAC size and integrity confirmed by pulse field gel electrophoresis (PFGE). Mutations in Pit-1 155 
binding sites were confirmed by sequencing. The following two primer sets (italics denote homology 156 
arm sequence) were used for primary and secondary recombination respectively;  157 
 158 
Chimeric PrlGalK-F GAAATCGTAACTGATAAAAAATCAGCTT 159 
GACTATATCTATTGATTCTCAGACCTGTTGACAATTAATCATCGGCATAGTATATCG. 160 
Chimeric Prl GalK-R 161 
GTCTCACGGTTTTCTCTTTCCCAGATATTGGCTTTATAAACCTTTGATATCTTCTCAGCAC 162 
TGTCCTGCTCCTTGTGA.  163 
Chimeric Pit1-3-F GAAATCGTAACTGATAAAAAATCAGCTTGACTATAT 164 
CTATTGATTCTCAGACTCACCTTCATCTTTCTCTC.  165 
Chimeric Pit1-1-R GTCTCACGGTTTT 166 
CTCTTTCCCAGATATTGGCTTTATAAACCTTTGATATCTTCAGGTACCGAATGAATCAGGC.  167 
 168 
Site-Directed Mutagenesis 169 
The hPRL 5kb Luc plasmid used for generation of the 256bp intermediate hPRL promoter sequence 170 
has been described previously [29]. Site mutations were induced in the three Pit-1 binding sites 171 
contained within the 256bp region [13, 30] present in the proximal pituitary promoter (-250/+1) using 172 
the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene, Cambridge, UK) following the 173 
manufacturers guidelines. Oligonucleotides used for the mutation of Pit-1 sites are shown below.    174 
Site 1, 5′-gcctgattcattCGCtAcCtgaagatatcaag-3′; site 2, 5′-tcttcctgaatatgGatCCgaaataaaatacc-3′; site 175 
3, 5′-cttttggcctaatCCatGGaaatccttcctag-3′. Capital letters represent mutated bases which resulted in 176 
the introduction of unique restriction sites as Kpn1, BamH1 and Nco1 respectively. These restriction 177 
sites were subsequently used for screening the mutated clones.  The 256bp region with mutated Pit-1 178 
binding sites was amplified with BAC homology arms appended to primers and recombineered into 179 
the hPRL BAC Luc construct with deleted proximal promoter. 180 
 181 
Cell culture and generation of stably transfected BAC cell lines 182 
Pituitary GH3 cells were maintained in phenol red-free DMEM with pyruvate/glutamine and 10% 183 
fetal bovine serum (FBS). Jurkat cells were cultured in RPMI (Life Technologies Inc., Gaithersburg, 184 
MD) supplemented with glutamine and 10% FCS. Serum starving conditions were in media 185 
containing 0.25% BSA in place of FBS. 186 
 187 
For stable transfection of cell lines, BAC DNA (hPRL WT BAC or PitProKO BAC) was prepared by 188 
maxiprep (BAC100 Nucleobond kit, Macherey-Nagel, Germany) and 3 µg was used to transfect 106 189 
GH3 cells in a 10cm dish or 2 × 106  Jurkat cells in 25cm2 flask using ExGen500 transfection reagent. 190 
Media was changed 48h post transfection and supplemented with 500 µg/ml G418. Media + antibiotic 191 
were refreshed every 3-4 days. Colonies formed 2-3 weeks after culturing in selective media were re-192 
cloned into individual wells of a 48 well plate. The stable transfectant clones which were found 193 
positive for Luc expression were sequentially scaled up to large culture vessels as necessary. 194 
195 
Endpoint luminometry assays 196 
GH3 cells (1×106) were washed once with PBS then lysed using 200µl of lysis buffer (25mM 197 
Tris/PO4, 10 mM MgCl2, 5 mm EDTA, 15% glycerol, 0.1% Triton X-100, and 0.1 mg/ml BSA). Cell 198 
lysis was aided by agitation at room temperature for 15 minutes, ATP added to a final concentration 199 
of 1mM and luciferase activity of samples measured using a FLUOstar Omega (BMG Labtech). Each 200 
experiment was performed in duplicate in three independent studies.  201 
 202 
Live-cell luminometry assays 203 
Pituitary GH3 cells (1.5×104 per well) were seeded into 96-well microplates (white opaque, 204 
PerkinElmer) in serum-free media containing 1mM luciferin (Biosynth). After 24 hours (h) cells were 205 
stimulated as indicated and microplates sealed with Breathe-Easy sealing film (Sigma). Luciferase 206 
activity from each well was measured using FLUOstar Omega (BMG Labtech) over a period of 24h 207 
while maintaining the cells at 37C in the presence of 5% CO2. Photon counts from each well were 208 
integrated over 5 seconds (s) after every 15 minutes (min). Results are shown as mean fold induction 209 
relative to an untreated control and represent triplicates of three independent experiments. 210 
 211 
ChIP assay 212 
GH3 cells containing hPRL WT BAC or hPRL PitProKO  BAC (3.5× 106) were seeded in 10cm 213 
dishes and left for 48h. ChIP assay was performed as described previously [31] based on the protocol 214 
by Upstate Biotechnology. Immunoprecipitation was carried out using 5 µg of either anti-Pit-1(X-7; 215 
Santa Cruz) or a non-specific IgG (Santa Cruz). DNA was purified and amplified by PCR with the 216 
following primers: Pit-1 3 forward 5’-AAATCCTTCCTAGAATGTTC-3′ and Pit1 1 Reverse 5′- 217 
AATCAGGCATTCGTTTC-3 ′  amplifying 145 bp of DNA.; rat GAPDH forward 5 ′ - 218 
GAAATGGGCTTAGGGGTGAT-3′   and reverse 5′- TTAAGGATGGCCTTGGACTG-3′. 219 
 220 
RT-PCR 221 
Total mRNA was extracted from GH3 and Jurkat cells stably transfected with PRL-Luc BAC or 5kb 222 
Null BAC using an RNeasy kit (Qiagen, Valencia, CA). Genomic DNA was removed using gDNA 223 
eliminating columns provided with the kit. First strand cDNA was synthesized using random octamers 224 
in VILO Superscript II (Life technologies). RT-PCR for the detection of pituitary or extra-pituitary 225 
derived Luciferase mRNA was performed using forward primer 98 [7] in PRL exon- 1a and reverse 226 
primer 11 [18] in the Luciferase gene. 227 
 228 
Real time luminescence imaging 229 
GH3 BAC transfectant cells and collagenase dispersed primary pituitary cells were cultured in 35mm 230 
glass coverslip-based dishes (Greiner Bio-One, UK) in the presence of 10% FBS. Luciferin (1mM) 231 
was added at least 10h before the start of the imaging. Cells were transferred to a Zeiss Axiovert 200 232 
microscope in a dark room, equipped with an incubator maintained at 37C, 5% CO2 in humid 233 
atmosphere. A bright-field image was taken before and after the luminescence imaging to track the 234 
localisation of cells. Luminescence images were obtained using a Fluar 10x, 0.75 NA objective. 235 
Images were captured using a photon-counting charge coupled device camera (Orca II ER, 236 
Hamamatsu Photonics, UK). Sequential images, each integrated over 10 min, were acquired using 237 
Kinetic Imaging software AQM6 (Andor, Belfast, UK). The same software was used for the analysis 238 
of the imaging data. Regions of interest were drawn around each single cell, and total photon counts 239 
for individual cell areas were obtained from each image. Mean luminescence intensity data were 240 
collected after the average instrument dark count (corrected for number of pixels being used) was 241 
subtracted from the luminescence signal. Each imaging experiment was performed at least 3 times, 242 
with a representative experiment presented in figures.  243 
 244 
Real-time luminescence imaging of primary bone marrow cells from hPRL-Luc transgenic rats  245 
The generation of hPRL-Luciferase rats has been described previously [18]. Bone marrow (BM) cells 246 
were harvested from male hPRL-Luc rats, and erythrocytes were removed with ammonium chloride 247 
lysis solution. BM cells were cultured in RPMI 1640 containing 10% (V/V) FBS in 35mm glass 248 
coverslip based dishes (Greiner Bio-One, UK) and left to adhere. Luciferin (1mM (Biosynth)) was 249 
added at least 6h before the start of the experiment. Cells were imaged with a Zeiss Axiovert 200, 250 
equipped with an XL incubator (maintained at 37C in a 5% CO2 in humidified conditions) in a dark 251 
room. Luminescence images were collected using a Fluar 10×, 0.5-NA objective (Zeiss), and captured 252 
using a photon-counting charge coupled device camera (Orca II ER; Hamamatsu Photonics). 253 
Sequential images were taken with a 30 minute integration period, then analysed using Kinetic 254 
imaging software AQM6 (Andor). Lipopolysaccharide (LPS) was added directly to the dish (0.05% 255 
final concentration. Imaging experiments were performed 3 times, with a representative experiment 256 
shown in Figure 1b.  257 
 258 
Pit-1 siRNA knockdown 259 
For siRNA transfections 1.5x105 hPRL WT GH3 cells were seeded into 12 well plates with 15pmol of 260 
Pit-1 Stealth RNAiTM (ThermoFisher Assay ID HSS108266) in the presence of Lipofectamine 261 
RNAimax reagent (ThermoFisher Scientific) according to the manufacturers’ protocol. Cells were 262 
also transfected in the same manner with Stealth RNAiTM siRNA negative control, medium GC 263 
duplex to control for sequence independent effects. Seventy two hours after transfection cells were 264 
used for live cell luminescence imaging experiments or lysed to assess the efficiency of Pit-1 265 
knockdown. 266 
 267 
Cell lysis and immunoblot analysis 268 
After transfection with either Pit-1 siRNA, siRNA negative control or lipofectamine RNAimax 269 
reagent only, hPRL-WT GH3 cells were lysed with Laemlli sample buffer (2% SDS, 60mM Tris-Cl 270 
(pH 6.8) 0.02% bromophenol blue, 0.1M DTT). Proteins were resolved by SDS-PAGE, transferred to 271 
nitrocellulose and blocked in 5% non-fat milk. Blots were incubated in primary antibodies over night 272 
at 4oC (Abcam), washed and then incubated with horse radish peroxidase conjugated secondary 273 
antibodies and developed using enhanced chemiluminescence. Efficiency of Pit-1 knockdown was 274 
assessed in at least 3 experiments. 275 
 276 
Stochastic switch model analysis 277 
To quantify the duration of transcriptional phases raw single-cell luminescence data from 3 278 
independent experiments for each imaging condition (hPRL WT, PitProKO, hPRL WT Pit-1 279 
knockdown and hPRL WT scrambled siRNA experimental conditions) was analysed using a 280 
previously developed stochastic switch model (SSM) [32]. This model utilized a reversible jump 281 
Markov chain Monte Carlo algorithm using back-calculated transcription rates from an observed 282 
luciferase signal to identify transcriptional switches, using known luciferase protein and mRNA 283 
degradation rates previously reported in GH3 cell lines, as used in the present study [32]. This 284 
analysis was performed using Matlab 2014a software (MathWorks), including the Bioinformatics and 285 
Statistical toolboxes.  286 
Results 287 
 288 
Contrasting cycles of hPRL transcription directed by the alternative and proximal promoters 289 
Pulsatile cycles of prolactin transcription have previously been shown in single cells from pituitary 290 
cell lines and in primary pituitary cells [17-20, 29, 33-36]. hPRL promoter directed reporter gene 291 
expression has also been observed in primary cultures of bone marrow myeloid cells (taken from 292 
transgenic rats expressing luciferase under the control of the hPRL WT BAC), where it is driven by 293 
the alternative promoter. This expression is significantly enhanced through cytokine stimulation, such 294 
as LPS treatment [34]. 295 
 296 
The first aim was to compare the dynamic behaviour of the wild-type hPRL promoter (hPRL WT 297 
BAC) in pituitary and non-pituitary cells, using primary pituitary cells and bone marrow myeloid cells 298 
from hPRL WT BAC transgenic rats (Figure 1, a and b). Pulsatile cycles of transcriptional activity 299 
were observed with bursting characteristics in both systems (Figure 1, c and d). However, comparison 300 
of the observed transcription cycles suggested a shortening of the ‘on period’ in extra-pituitary cells, 301 
in which cycles of transcription are driven by the alternative promoter (Figure 1, e and f).  302 
 303 
Generation of the proximal-promoter knock-out hPRL BAC Luc (hPRL PitProKO BAC) construct 304 
In order to evaluate the influence of promoter architecture on transcriptional bursting the hPRL WT 305 
BAC was modified to delete the entire 5kb proximal pituitary promoter, leaving the upstream exon 1a 306 
and the alternative promoter intact (Figure 2a). This provided a construct in which luciferase 307 
expression was directed from the upstream alternative hPRL promoter, enabling direct comparison 308 
with the hPRL WT construct. The hPRL proximal promoter contains an alternative splice acceptor 309 
site (ASAS) at position -246 relative to its transcription start site, which is important for the function 310 
of the alternative promoter [18] (for diagrammatic analysis of the region and constructs see Figure 3). 311 
In addition, this region contains three Pit-1 binding sites, which could have the potential to drive 312 
expression from the pituitary promoter. We therefore performed site-directed mutagenesis to remove 313 
the three Pit-1 binding sites in the hPRL Luc 5kb plasmid (described previously [29], Figure 2b). 314 
After mutation, a 256bp DNA sequence containing the ASAS and mutated Pit-1 binding sites was 315 
amplified from the hPRL Luc 5kb plasmid and inserted into the hPRL Luc BAC with the 5kb pituitary 316 
promoter region deleted (Figure 2c). Chromatin immunoprecipitation (ChIP) confirmed absence of 317 
Pit-1 binding to the mutated construct (Figure 2d). The resulting hPRL BAC, termed PitProKO BAC, 318 
expresses luciferase under the control of the alternative promoter, and contains the ASAS and mutated 319 
Pit-1 sites. The remaining putative Pit-1 binding sites in the alternative promoter have previously been 320 
found to be non-functional [7], and were therefore not removed or mutated.  321 
 322 
The hPRL alternative promoter is active in GH3 pituitary cells independently of Pit-1 323 
The hPRL alternative promoter is often referred to as the extra-pituitary promoter, based on the notion 324 
that its activity is confined to sites outside of the pituitary. Here, to assess the contribution the 325 
alternative promoter plays in the transcriptional regulation of the hPRL gene in the pituitary, we 326 
generated rat pituitary GH3 stable cell lines expressing hPRL WT BAC-Luc or hPRL PitProKO 327 
BAC-Luc. Incorporation of the entire BAC without truncation into the cell lines was confirmed 328 
following genomic DNA extraction, with PCR using primer sets spanning the entire BAC construct, 329 
including the deleted 5kb region (Supplemental, Figure S1). The luciferase expression levels of three 330 
WT and three PitProKO clonal GH3 cell lines were compared. All cell lines displayed high and 331 
fluctuating levels of reporter gene activity (Figure 4a-e). However, WT clonal lines showed markedly 332 
higher luciferase activity compared with PitProKO clones (as seen in Figure 4a-b, with quantitative 333 
luminometry in Figure 4e). These data confirm that the alternative promoter is active in pituitary cells, 334 
but that the activities of both promoters are required for higher-level gene expression.  335 
 336 
To confirm bona fide alternative promoter activity, RT-PCR was performed using GH3 hPRL WT 337 
cells and a primer set to amplify from exon1a and a portion of the luciferase gene. A single 423bp 338 
product was detected that corresponded to the splicing of exon1a into exon 1b, thus bypassing the 339 
pituitary 5´UTR sequence which contains Pit-1 binding sites (Supplemental Figure 1b). A single 340 
product (670bp) was also detected in the non-pituitary lymphoblastoid Jurkat cell line expressing the 341 
hPRL WT construct. This was 246bp longer than its pituitary counterpart and corresponded to a 342 
splicing of exon 1a to a position -246bp upstream of transcriptional start site. These results together 343 
show that luciferase expression observed from PitProKO cells is representative of hPRL alternative 344 
promoter activity, and that both proximal and alternative promoters contribute towards hPRL directed 345 
luciferase activity in GH3 pituitary cells.  346 
 347 
Functional activation of the alternative promoter in GH3 PitProKO cells was confirmed by measuring 348 
the transcriptional response to appropriate stimuli. Induction was markedly greater in hPRL-WT cells 349 
where both promoters were present (Supplemental Figure S2a). The PitProKO promoter was non-350 
responsive to both estradiol (E2) and tumour necrosis alpha (TNFa) treatment (Supplemental Figure 351 
S2b), supporting our previous studies demonstrating that the hPRL transcriptional response to these 352 
stimuli is mediated by an estrogen response element (ERE) in the proximal promoter (-1189 bp from 353 
the transcription start site), which is not present in the PitProKO construct [17, 37].  354 
 355 
The hPRL alternative promoter displays bursting gene transcription 356 
We have previously shown the pulsatile nature of hPRL transcription in pituitary cells using both 5kb 357 
and BAC constructs in pituitary cell lines and in normal pituitary tissue in transgenic rats (17, 20, 25, 358 
27-32). The recombinant BAC constructs allowed us to test whether this bursting transcriptional 359 
behaviour was specific to activity directed by the proximal promoter and whether Pit-1 binding 360 
elements were required. Real-time luminescence imaging was conducted over 20h periods in living 361 
cells to directly compare the dynamics of luciferase expression from single unstimulated hPRL WT 362 
and PitProKO cell lines (Figure 4a-d). Cyclical patterns of transcriptional activity were observed in 363 
both cell lines, with lower amplitude in the PitProKO cells (normalised data shown in Figure 4c and 364 
d). The amplitude difference was comparable to the difference in luciferase activity observed between 365 
hPRL WT and PitProKO clonal cell lines seen in luciferase assays (Figure 4e). In addition to a 366 
reduction in amplitude, analysis of single cell traces also revealed that the active ‘on’ periods of gene 367 
transcription appeared significantly shorter in PitProKO cells than in WT cells, in other words that the 368 
pulses seemed to be shorter and sharper than in the WT cells (Figure 4c and d insets). To quantify the 369 
differences in transcription timing between the two promoters, single-cell luminescence data was 370 
analysed using a previously described stochastic switch model (33). This modelling analysis 371 
confirmed a significant reduction in the ‘on’ time of the PitProKO promoter compared to WT cells 372 
(Figure 4f), confirming the initial impression that the peaks of transcriptional activity were briefer. 373 
These data show that the hPRL alternative and proximal promoters both generate cyclical patterns of 374 
transcription, but that transcription in the absence of Pit-1 binding occurs at a reduced rate, with 375 
significantly shorter periods of active transcription in any given cycle.  376 
 377 
Binding of the pituitary-specific transcription factor Pit-1 to cis-acting regulatory elements plays a 378 
key role in prolonging the duration of ‘on periods’ of active gene transcription  379 
One major factor that could explain these differences in transcription timing was the presence or 380 
absence of Pit-1 binding to the different hPRL promoters, in different cell contexts. We hypothesised 381 
that rather than simply being required for pituitary hPRL gene expression, Pit-1 might also play a role 382 
in the timing of transcription and contribute to the stabilisation of efficient and productive 383 
transcription cycles. To test this possibility, siRNA was used to knock down Pit-1 expression in both 384 
cell lines, comparing the behaviour of the WT and PitProKO constructs (Figure 5). 385 
 386 
Knockdown of Pit-1 reduced transcriptional activity of the WT BAC construct, as seen in 387 
luminometry assays (Figure 5e), where Pit-1 expression was successfully reduced by greater than 95% 388 
(Figure 5e inset). Quantitative analysis of single-cell transcriptional data by SSM confirmed that 389 
knockdown of Pit-1 resulted in a significant shortening of the on-period of transcription (Figure 5f), 390 
consistent with the findings from the BAC mutagenesis studies. The PitProKO BAC contains mutated 391 
Pit-1 binding sites; therefore knockdown of Pit-1 in these cells should have no effect on the timing of 392 
reporter gene expression. SSM analysis of single-cell imaging data showed no difference in the on-393 
periods of active transcription between PitProKO cells and in PitProKO cells in which Pit-1 394 
expression was successfully knocked down  (Supplemental Figure 3). 395 
 396 
Asymmetry between activation and deactivation during a transcriptional pulse  397 
In previous work [21] on the transcription of human growth hormone we identified an asymmetry in 398 
the number and size of rate-increasing and rate-decreasing switches, resulting in a predominance of an 399 
all-or-nothing activation step, followed by a multi-step graded reduction. We therefore investigated if 400 
there was such an asymmetry in the current system. To do this, each dataset (WT, PitProKO, WT-Pit-401 
1 knockdown and WT scrambled siRNA) was processed by the SSM, and to each switch in the 402 
transcription rate we associated a score S which is the ratio of the change in the rate to the highest of 403 
the rates before and after the switch. Thus, a switch with S close to 1 is more binary (complete) while 404 
one with a smaller S is partial. We found that for each construct and condition considered, the 405 
distributions of S for up and down switches were significantly different with the asymmetry clearly 406 
present. The down switches had substantially more partial events than the up switches which were 407 
dominated by complete switches (Figure 6). The distributions found for the PitProKO cells 408 
substantially differed from the other constructs. For both the up and down switches, there was a 409 
highly significant greater tendency for complete transitions and a binary response (Figure 6 m and n) 410 
when just the alternative promoter was available. This may be partly explained by the fact that the 411 
switches are smaller in magnitude. On the other hand, the distributions for the hPRL WT cells and 412 
those with the Pit-1 knockdown were very similar as can be seen from the cumulative distribution 413 
functions in Figure 6 m and n. This suggests that the proximal pituitary promoter is responsible for the 414 
more graded response seen in the WT, but that this response is not due to interaction of Pit-1 with the 415 
promoter. We hypothesise that the graded response is associated with extra transcriptional availability 416 
modulated by the proximal pituitary promoter, and that Pit-1 binding facilitates higher transcription 417 
rates during the pulses.   418 
Discussion 419 
 420 
Heterogeneity in gene expression within a cell population has been observed in numerous single-cell 421 
imaging studies where it has been shown in a diverse range of organisms that individual genes can be 422 
transcribed in short bursts of variable duration and frequency [19, 22-26, 36, 38]. Evidence supports 423 
several molecular mechanisms that together control and modulate transcriptional bursting, including 424 
nucleosome occupancy [39], chromatin modifications [19, 23, 40], transcription factor availability [23, 425 
26, 40, 41] and promoter structure [23] (reviewed in [42]. We have used pituitary cells as a model 426 
system and studied the transcriptional bursting from two alternative promoters in the hPRL gene, in 427 
the presence or absence of the pituitary-specific transcription factor Pit-1. Using live-cell imaging of 428 
stably transfected cells, we identified the role of prolactin promoter elements in the determination of 429 
the transcriptional timing characteristics in single pituitary cells. We find kinetically distinct 430 
transcriptional bursting behaviour of the two alternative promoters within the prolactin gene, and that 431 
binding of Pit-1 to prolactin promoter elements prolongs the duration of ‘on-periods’ of active gene 432 
transcription. 433 
 434 
We previously generated a BAC reporter construct (hPRL WT) spanning 163 Kb of the human PRL 435 
genomic locus and engineered it to insert the luciferase reporter gene at the start of the hPRL exon 1b, 436 
thus preventing expression of the hPRL coding sequence [18]. We have studied the behaviour of this 437 
hPRL WT BAC reporter construct using in vivo and in vitro models [18, 20, 33, 34]. Whole body in 438 
vivo imaging of hPRL-luc BAC-transgenic rats using this construct revealed striking evidence of 439 
alternative promoter activation after immune challenge, demonstrating that this construct can display 440 
transcriptional control by both the exon 1b promoter and the alternative upstream exon 1a promoter 441 
[20, 34]. In order to determine the relative contributions of the two alternative promoter regions, in the 442 
present study we engineered the hPRL-luc BAC (referred to as the WT construct) by deleting the 443 
entire 5 kbp region of proximal promoter and inserting a 256 bp DNA fragment which contained 444 
alternative splice acceptor site and mutated non-functional Pit-1 binding sites (hPRL PitProKO BAC). 445 
This strategy resulted in a functional upstream exon 1a promoter driving the luciferase reporter gene 446 
and hPRL gene exons and introns, together with 115kb upstream and 38 kb downstream flanking 447 
regions, but no functional Pit-1 responsive elements. The initial assumption in this work was that the 448 
two promoters in the hPRL gene locus would display clear differential cell-type-specific activation, 449 
namely that the exon 1b promoter with its multiple Pit-1 binding sites would generate ‘pituitary-450 
specific’ activation, and that the upstream exon 1a promoter, which lacks Pit-1 binding sites, would be 451 
active only in non-pituitary cells [10]. The recombinant BAC approach also allowed us to evaluate 452 
possible differences in transcriptional timing in relation to promoter structure and transcription factor 453 
binding.  454 
Alternative promoters are a common occurrence in the mammalian genome and can allow diversity 455 
and flexibility in gene expression [43, 44]. The hPRL proximal and distal promoter regions differ 456 
greatly in their architecture with distinct enhancer and regulatory region configuration (Supplemental 457 
Figure 1). A major difference is the presence of multiple Pit-1 binding sites in the proximal promoter 458 
region. We have shown here that the alternative ‘non-pituitary’ promoter is transcriptionally active in 459 
pituitary cells, albeit at a greatly reduced level. This suggests that the two hPRL gene promoters 460 
display tissue preference rather than absolute tissue specificity in activation. This phenomenon of 461 
tissue preference rather than tissue exclusivity has been reported in a variety of human genes [43]. 462 
Single-cell analysis of reporter gene expression confirmed that both promoters displayed 463 
heterogeneous and bursting transcriptional activity, with the alternative promoter associated with a 464 
significantly reduced transcriptional ‘on’ time and a more binary response. The short ‘on’ timing 465 
appears to be a specific feature of alternative ‘non-pituitary’ promoter activity as similar timing 466 
characteristics were observed in primary bone marrow myeloid cells from hPRL-WT transgenic rats 467 
(Figure 1).  468 
 469 
The activity of Pit-1 is regulated in response to signal-transduction pathways by its interaction with 470 
co-repressor and activator complexes containing nuclear receptor co-repressor 1 (N-CoR) and CREB 471 
binding protein (CBP) respectively [45]. In response to physiological stimuli Pit-1, through its 472 
interaction with activator complexes uses the histone acetyltransferase function of CBP [45]. Pit-1 has 473 
been reported to direct changes in the chromatin structure of the hPRL promoter [46], and changes in 474 
chromatin structure have been implicated in the timing of hPRL gene transcription [19]. In this work 475 
we examined the effect of modifications of promoter structure by inactivation of Pit-1 binding sites, 476 
as well as reduction of transcription factor availability in Pit-1 knockdown experiments. The evidence 477 
presented here shows that burst timing is affected by the number of transcription factor binding sites 478 
and transcription factor availability. Binding of transcription factors to regulatory regions can 479 
influence burst frequency [27] and burst size [40, 47] with differences in function possibly specific to 480 
certain transcription factors. Previously we have shown that pulsatile patterns of hPRL gene 481 
expression change during development; nascent primary pituitary lactotroph cells (embryonic day 482 
16.5, from transgenic reporter rats) show ‘short’ bursts of transcriptional activity, whereas later in 483 
development and in adult pituitary tissue a more stable transcription phenotype is observed [20, 33]. 484 
Pit-1 mRNA is first detected in the rat anterior pituitary at embryonic day 15 and the protein is 485 
initially expressed at very low levels [48]. Our data suggest that the difference seen in transcriptional 486 
bursts during development could be due to the availability of the Pit-1 transcription factor.  487 
 488 
An important finding of the present work was that manipulation of the promoter structure had clear 489 
effects on the timing and structure of transcriptional cycles in living, intact cells. We and others have 490 
previously found that the prolactin gene, like other genes studied, displays cycles of transcriptional 491 
activity that are likely to involve chromatin remodelling [19, 23, 36, 49]. The question arises as to 492 
what elements of promoter structure may control the existence or timing of these cycles. Pit-1 is a 493 
well-studied transcription factor thought to be necessary for tissue-specific expression of the prolactin 494 
gene in the pituitary. The prolactin gene proximal promoter contains multiple Pit-1 binding sites that 495 
are thought to mediate responses to signalling stimuli [4]. Deletion of the Pit-1-regulated promoter 496 
elements in the human prolactin gene locus did not prevent transcriptional cycles from occurring, but 497 
did markedly reduce the duration of active periods of transcription, modelled here as ‘on’ periods 498 
using a stochastic switch model, and also resulted in a less graded, more binary, response profile. This 499 
suggests that Pit-1 binding in the ‘pituitary-specific’ promoter is important to stabilise transcriptional 500 
complexes for longer periods to allow higher rates of transcription to occur, and our data are the first 501 
to indicate that the action of this transcription factor has an important effect on timing.  502 
 503 
An important challenge is to assess the physiological significance of pulsatile transcription and the 504 
role that its modulation may play on normal physiology. The present studies were performed in the 505 
pituitary GH3 cell line, which has significant limitations: it is an immortalised clonal cell line, and the 506 
cells lack functional dopamine receptors. Nonetheless, they have proved a valuable test-bed in which 507 
to explore how pituitary hormones may be regulated, and a system in which complex genetic 508 
manipulations may be trialled before conducting studies in living animals. In our previous work using 509 
transgenic hPRL-EGFP reporter rats, we have found identical transcriptional pulses in living intact 510 
normal pituitary cells [18, 20, 33, 36]. In addition to studying the effects of tissue structure and 511 
development on dynamic transcriptional patterns, we showed how modification of pulse charateristics 512 
in individual cells changes the overall mRNA production in a larger population of cells (36). 513 
Important questions still to be addressed in vivo include studies on the effects of oestrogen and 514 
dopamine, and also how hormone production by clonal pituitary tumours might differ from that of 515 
lactotrophs in the intermingled cell populations of the normal pituitary. This work will require further 516 
use of such animal models, but in the meantime our cell line data indicate that transcriptional timing is 517 
an important aspect of overall physiological control of pituitary hormone production, and that 518 
transcription factors such as Pit-1 appear to have a key role in stabilising transcriptional pulses to 519 
ensure high-level hormone production.  520 
 521 
In summary, Pit1 plays an important role in the timing of transcription cycles, rather than simply 522 
being necessary to permit tissue-specific gene expression. The proximal promoter displays a binary 523 
(‘all-or-nothing’) activation step, with the presence of Pit-1 and Pit-1 binding sites associated with 524 
prolongation of the subsequent ‘on-phase’, and multi-step graded inactivation. In the absence of Pit-1 525 
or Pit-1 binding, as occurs with the alternative upstream promoter in non-pituitary tissues, both the 526 
activation and inactivation steps of the transcriptional cycles have binary characteristics of a smaller 527 
amplitude. Pit-1 is localised in nuclear foci and dynamically partitioned, with a key role in interacting 528 
with the nuclear matrix [50]. In addition, Pit-1 has been shown to reorganise long range looping [51], 529 
nuclear co-repressors [52], nucleosome location and  histone acetylation [46]. The current results 530 
suggest a dynamic rather than passive role for Pit-1 in transcriptional regulation. These results may be 531 
applicable to the mechanism of action of other master cell-lineage specific transcription factors and to 532 
the dynamic behaviour of genes which are differentially expressed through alternative promoters.   533 
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Figure Legends 664 
 665 
Figure 1 666 
Contrasting cycles of hPRL transcription directed by the alternative and proximal promoters 667 
Luminescence signal from primary pituitary (a) and bone marrow (BM) myeloid cells (following 668 
treatment with 0.05% LPS) (b), taken from transgenic rats expressing luciferase under the control of a 669 
160kb hPRL genomic fragment (hPRL WT BAC). Coloured lines represent data from single cells (c 670 
n=45 cells; d, n=12 cells) and thick black line represents the population mean. Example single cell 671 
traces from pituitary cells (e) and BM myeloid cells (f). Luciferase activity from each cell was 672 
normalised to the average luminescence intensity of all cells in each imaging experiment at time zero.  673 
 674 
 675 
Figure 2 676 
Generation of the hPRL PitProKO-Luc BAC 677 
Schematic illustration of the knock-out of the prolactin proximal pituitary promoter using a 160kb 678 
hPRL BAC-Luc construct (hPRL WT). 5kb pituitary promoter sequence was replaced with positive 679 
selection marker Galk, via a seamless BAC recombineering strategy to knock-out the PRL pituitary 680 
promoter (a). Site-mutations were introduced in the three Pit-1 binding sites present in the proximal 681 
pituitary promoter (-256/+1) using hPRL 5kbLuc plasmid (b). 256 bp DNA fragment containing 682 
mutated Pit1 sites along with alternative acceptor site was amplified from hPRL 5kb Luc plasmid 683 
using BAC homology arms and inserted into the pituitary promoter knock-out BAC replacing the 684 
Galk gene, thereby creating a construct expressing luciferase under the control of the extra-pituitary 685 
promoter (PitProKO) (c). GH3 cells containing hPRL WT or hPRL PitProKO BAC constructs were 686 
fixed in 1% formaldehyde and subjected to ChIP with either non-specific IgG antibody or Pit-1 687 
specific antibody. DNA was extracted and amplified by primers flanking the first and third pit-1 688 
binding sites or a non-specific rat GAPDH sequence (d). GalK, galactokinase; Luc, luciferase. 689 
 690 
Figure 3 691 
Schematic of the regulatory elements within the hPRL pituitary and extra-pituitary promoter 692 
regions. 693 
Schematic of the hPRL promoter illustrating pituitary and extra-pituitary regions (a). Response 694 
elements within the pituitary promoter that enable expression of PRL in the pituitary (adapted from 695 
[4]) (b). Response elements within the extra-pituitary region that enable expression of PRL in extra-696 
pituitary tissues (adapted from [53]) (c). Schematic of the hPRL-Luc 160kb BAC expressing 697 
luciferase under the control of the entire hPRL gene (d). AP1, activator protein 1; cEBPb, CCAAT 698 
binding protein beta; CRE, cAMP response element; ER, estrogen receptor; FOXO1A, forkhead box 699 
protein O1A; GR, glucocorticoid receptor; HNF-3, hepatocyte nuclear factor 3; NFkB, nuclear factor 700 
kappa-light-chain-enhancer of activated B cells; NF-Y, nuclear factor Y; TGIF, TG-interacting factor; 701 
TRF, TBP (TATA binding protein)-related factor; PR, progesterone receptor.  702 
 703 
Figure 4 704 
Bursting gene transcription of the hPRL alternative promoter 705 
Single cell transcriptional activity in GH3 hPRL WT and PitProKO cell lines. Representative images 706 
and single cell transcriptional traces from hPRL WT (4a and c) and hPRL PitProKO cells (4b and d). 707 
Coloured lines represent data from single cells with the thick black line representing the mean 708 
response of the population; n=16 (c), n=28 (d). Luciferase activity from three individual hPRL WT 709 
and three hPRL PitProKO clonal GH3 cell lines (e). Luciferase activity from each cell was normalised 710 
to the average luminescence intensity of all cells in each imaging experiment at time zero. Estimated 711 
transcriptional ‘on’ time determined by SSM compared between hPRL WT and PitProKO cells. Bars 712 
show standard deviation of the cycle length from 56 and 69 cells respectively in three experiments per 713 
cell type. The duration of an ‘on’ phase is significantly reduced in PitProKO cells (Kolmogorov-714 
Smirnov, *P < 0.05) (f). 715 
 716 
Figure 5 717 
Pit-1 binding regulates the timing of hPRL transcription 718 
Single-cell transcriptional activity of hPRL WT cells following siRNA Pit-1 knockdown or siRNA 719 
negative control, 72 hours after transfection. Representative images and single-cell transcriptional 720 
traces from siRNA negative control treated hPRL WT (a and c) and hPRL WT, Pit-1 siRNA 721 
knockdown cells (b and d). Coloured lines represent data from single cells with the thick black line 722 
representing the mean response of the population; n=30 cells (c), n=22 cells (d). Luciferase activity 723 
from each cell was normalised to the average luminescence intensity of all cells in each imaging 724 
experiment at time zero. Luciferase activity (e) and Pit-1 protein expression ((e) inset) of hPRL WT 725 
cells following treatment with lipofectamine transfection reagent, siRNA negative control or Pit-1 726 
siRNA knockdown (KD: knockdown). Estimated transcriptional ‘on’ time determined by SSM, 727 
compared between hPRL WT scrambled siRNA, and hPRL WT siRNA Pit-1 knockdown. Bars show 728 
standard deviation of the cycle length from 77 and 62 cells respectively in three experiments per cell 729 
type. The duration of an ‘on’ phase is significantly reduced in cells with Pit-1 knockdown 730 
(Kolmogorov-Smirnov, *P < 0.05) (f).  731 
 732 
Figure 6 733 
Distribution of the switching score S for up and down switching for each of WT, PitProKO, WTPit-1 734 
knockdown and WT scrambled siRNA. a,d,g,j: the distributions of scores S for up switches for each 735 
of the four datasets. b,e,h,k: as before (a,d,g,j) but for down switches. c,f,i,l: cumulative distribution 736 
functions for each of the four datasets. In each case there is a significant difference between the up 737 
and down switches, with up switches having larger values of S. m: a comparison of the cumulative 738 
distribution functions of the four datasets.   739 
Supplemental Figure Legends 740 
 741 
Figure S1 742 
Characteriation of pituitary (GH3) hPRL PitProKO and WT stable cell lines 743 
Schematic representation of hPRL BAC indicating primer sets directed to amplify regions along the 744 
hPRL promoter to confirm full incorporation of the BAC into cells lines (a). RT-PCR using genomic 745 
DNA extracted from PitProKO clonal cell lines with primer sets illustrated as in (a). Primer set 3 was 746 
directed against the proximal promoter region that is deleted in the PitProKO construct. Transfectant 747 
cells, highlighted in the box, showing amplification of each of the primer sets, excluding set 3 full 748 
were used in subsequent experiments. hPRL PitProKO and WT BAC DNA, used for transfection of 749 
cell lines served as positive controls (b). Extra-pituitary-specific RT-PCR, using a primer set to 750 
amplify from exon1a and a portion of the luciferase gene [18] in pituitary GH3 hPRL WT cells and 751 
the extra-pituitary human jurkat cell line (expressing luciferase under the control of the hPRL WT 752 
BAC) (c) 753 
 754 
Figure S2  755 
hPRL WT and PitProKO response to well characterised hPRL regulating stimuli 756 
Stimulation of three individual serum starved (24h) hPRL WT (a) and PitProKO cell lines (b). 757 
Luciferase activity was measured 16 hours post treatment with the following stimuli ;0.1% DMSO; 758 
10ng/ml PMA; 10ng/ml FGF-2; 5µM FSK; 10nM Dex; 10nM E2 and 10ng/ml TNFα. Results are 759 
shown as fold induction +/- SD from an untreated control sample. Values represent the mean of at 760 
least three independent experiments, each with three replicates. Each bar represents an individual 761 
clone. Live cell luminometry of serum-starved (24h) hPRL WT BAC1 (c) and hPRL PitProKO BAC1 762 
(d) cell lines following treatment with 10nM E2, 10ng/ml TNFα alone and in combination. 763 
Measurements of luciferase activity were taken every 15 minutes with a five second integration. 764 
Results are shown as fold induction +/- SD from the untreated control sample with values representing 765 
the mean of at least three independent experiments, each with three replicates. 766 
 767 
Figure S3 768 
Comparison of hPRL PitProKO cell behaviour with and without Pit-1 knockdown 769 
Single-cell transcriptional activity of hPRL WT PitProKO cells following siRNA Pit-1 knockdown or 770 
siRNA negative control, 72 hours after transfection. Representative images and single-cell 771 
transcriptional traces from untreated hPRL PitProKO cells, ie with Pit-1 present (a) and hPRL 772 
PitProKO cells with Pit-1 siRNA knockdown (b). As before, coloured lines represent data from single 773 
cells with the thick black line representing the mean response of the population; n=26 cells and n=17 774 
cells respectively. Luciferase activity from each cell was normalised to the average luminescence 775 
intensity of all cells in each imaging experiment at time zero. Pit-1 and tubulin protein expression 776 
confirms knockdown (c). Estimated transcriptional ‘on’ time determined by SSM, compared between 777 
hPRL PitProKO, and hPRL PitProKO cells with siRNA Pit-1 knockdown. Bars show standard 778 
deviation of the cycle length from 69 and 17 cells respectively. The duration of an ‘on’ phase is not 779 
significantly affected by Pit-1 knockdown in the PitProKO cells that lack functional Pit-1 binding 780 
sites in the transgene (d).  781 
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